GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · Real-Time Price · USD
71.50
-4.77 (-6.25%)
At close: Oct 6, 2026, 4:00 PM EDT
71.52
+0.02 (0.03%)
After-hours: Oct 6, 2026, 4:00 PM EDT
GeneDx Holdings Revenue
GeneDx Holdings had revenue of $114.44M in the quarter ending June 30, 2026, with 11.44% growth. This brings the company's revenue in the last twelve months to $454.43M, up 25.42% year-over-year. In the year 2025, GeneDx Holdings had annual revenue of $427.54M with 39.97% growth.
Revenue (ttm)
$454.43M
Revenue Growth
+25.42%
P/S Ratio
4.72
Revenue / Employee
$349,558
Employees
1,300
Market Cap
2.13B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 427.54M | 122.09M | 39.97% |
| Dec 31, 2024 | 305.45M | 102.88M | 50.79% |
| Dec 31, 2023 | 202.57M | -32.13M | -13.69% |
| Dec 31, 2022 | 234.69M | 22.50M | 10.60% |
| Dec 31, 2021 | 212.20M | 32.87M | 18.33% |
| Dec 31, 2020 | 179.32M | -16.85M | -8.59% |
| Dec 31, 2019 | 196.17M | 62.83M | 47.12% |
| Dec 31, 2018 | 133.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| RadNet | 2.27B |
| Sotera Health Company | 1.22B |
| NeoGenomics | 766.30M |
| OPKO Health | 587.90M |
| Veracyte | 561.90M |
| CareDx | 458.09M |
| BillionToOne | 397.41M |
| Castle Biosciences | 357.28M |
WGS News
- 4 days ago - GeneDx to introduce Easy Order at AAP 2026 - TheFly
- 4 days ago - GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care - Business Wire
- 5 days ago - GeneDx price target raised to $83 from $74 at Guggenheim - TheFly
- 14 days ago - GeneDx selloff after CMS news ‘probably too extreme,’ says Craig-Hallum - TheFly
- 14 days ago - GeneDx falls -5.4% - TheFly
- 27 days ago - GeneDx, Beren Therapeutics launch NPC GenomeComplete - TheFly
- 27 days ago - GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C - Business Wire
- 4 weeks ago - GeneDx Holdings Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts